CN1732950A - Composition of cefuroxime sodium and tazobactam sodium for injection - Google Patents

Composition of cefuroxime sodium and tazobactam sodium for injection Download PDF

Info

Publication number
CN1732950A
CN1732950A CN 200510090388 CN200510090388A CN1732950A CN 1732950 A CN1732950 A CN 1732950A CN 200510090388 CN200510090388 CN 200510090388 CN 200510090388 A CN200510090388 A CN 200510090388A CN 1732950 A CN1732950 A CN 1732950A
Authority
CN
China
Prior art keywords
sodium
tazobactam
cefuroxime
injection
staphylococcus aureus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN 200510090388
Other languages
Chinese (zh)
Other versions
CN1315477C (en
Inventor
刘全胜
夏中宁
舒军
林学良
Original Assignee
夏中宁
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36075706&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1732950(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 夏中宁 filed Critical 夏中宁
Priority to CNB200510090388XA priority Critical patent/CN1315477C/en
Publication of CN1732950A publication Critical patent/CN1732950A/en
Application granted granted Critical
Publication of CN1315477C publication Critical patent/CN1315477C/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention provides a composition of cefuroxime sodium and tazobactam sodium for injection, which comprises cefuroxime sodium and tazobactam sodium by a weight ratio of 3:1 or 5:1. These compositions have better antibiotic action.

Description

Combination of Cefuroxime sodium and tazobactam for injection
Technical field
The present invention relates to a kind of antibacterial combination, is a kind of anti-beta-lactamase antibiotic composite preparation.
Background technology
(Cefuroxime CXM) is second generation cephalosporin to cefuroxime, as a kind of broad-spectrum sterilization antibiotic, gram positive bacteria and most gram negative bacteria is all had stronger antibacterial action, and liver, nephrotoxicity are low.Along with cefuroxime extensive use clinically, the original responsive bacterial strain of part has produced drug resistance to cefuroxime, and its antibacterial effect is descended.Discover that antibacterial produces chemical sproof main mechanism to cephalosporins medicine and decomposes medicine for producing specific beta-lactamase.
Produce the drug resistance that the beta-lactamase antibacterial is caused for overcoming, people begin to develop the anti-beta-lactamase antibiotic composite preparation of cefuroxime and Tazobactam Sodium composition, and obtained certain achievement, test shows that this compound preparation obviously is better than cefuroxime to in-vitro antibacterial and the bactericidal activity of staphylococcus aureus, colon bacillus, Klebsiella pneumonia, Pseudomonas aeruginosa, acinetobacter calcoaceticus, generation bacillus, shigella flexneri and the enterobacter cloacae of product enzyme.For example among the disclosed Chinese patent literature CN1513457A on July 21st, 2004, a kind of anti-beta-lactamase antibiotic composite preparation of being made up of cefuroxime and salt thereof and Tazobactam Sodium and salt thereof is disclosed.Think in this patent documentation that the preferred weight ratio scope of cefuroxime and salt thereof and Tazobactam Sodium and salt thereof is 1: 1 to 10: 1, best weight ratio is 2: 1, under this optimum weight ratio condition, this compound preparation is to the MIC of staphylococcus aureus, staphylococcus epidermidis, streptococcus pneumoniae, colon bacillus, Klebsiella pneumonia, Pseudomonas aeruginosa, acinetobacter calcoaceticus, generation bacillus, shigella flexneri and the enterobacter cloacae of product enzyme 50Minimum with MIC90.
The inventor is by studying for a long period of time and a large amount of test, found new best proportioning, under this conditions of mixture ratios, it is 2: 1 o'clock in-vitro antibacterial, bactericidal effect that the anti-beta-lactamase antibiotic composite preparation of Cefuroxime Sodium and sodium-tazobactam is better than the weight ratio of disclosed Cefuroxime Sodium and sodium-tazobactam among the CN1513457A to extracorporeal disinfecting, the antibacterial effect of the antibacterial that produces enzyme, and cost is lower, and patient Geng Yi accepts.
Summary of the invention
The drug-fast problem that directed toward bacteria produces Cefuroxime Sodium, the objective of the invention is to provide the compound preparation that a kind of combination of Cefuroxime sodium and tazobactam for injection constitutes, the in-vitro antibacterial of this preparation, bactericidal effect are equal to the effect of present similar preparation.
Cefuroxime sodium for injection provided by the invention and sodium-tazobactam compound preparation are made up of hot sodium of cephalo and sodium-tazobactam, and the weight ratio of described Cefuroxime Sodium and sodium-tazobactam is 3: 1 or 5: 1.
This cefuroxime sodium for injection of the present invention and sodium-tazobactam compound preparation, its in-vitro antibacterial and sterilization are better than existing Cefuroxime Sodium village sodium-tazobactam compound preparation, overcome and thought in the prior art that its best proportioning is 2: 1 a technical prejudice, and in the compound preparation price to face upward the consumption of expensive Tazobactam Sodium lower, thereby the unit administration cost is minimum, can alleviate patient's burden greatly.
The specific embodiment
Be described further below in conjunction with the compositions of specific embodiment hot sodium of this present invention's injection cephalo and sodium-tazobactam formation.
Embodiment 1
Combination of Cefuroxime sodium and tazobactam for injection is made up of Cefuroxime Sodium and sodium-tazobactam, and the weight ratio of Cefuroxime Sodium and sodium-tazobactam is 3: 1.
Embodiment 2
Combination of Cefuroxime sodium and tazobactam for injection is made up of Cefuroxime Sodium and sodium-tazobactam, and the weight ratio of Cefuroxime Sodium and sodium-tazobactam is 5: 1.
Comparative experimental example
Sample:
A: cefuroxime sodium for injection sodium-tazobactam (1: 1), Youbang Fukang Medicine Inst., Co., Ltd., Hainan provides, specification: the 1.0g/ bottle
B: cefuroxime sodium for injection sodium-tazobactam (2: 1), Youbang Fukang Medicine Inst., Co., Ltd., Hainan provides, specification: the 1.2g/ bottle
C: cefuroxime sodium for injection sodium-tazobactam (3: 1), Youbang Fukang Medicine Inst., Co., Ltd., Hainan provides, specification: the 1.0g/ bottle
D: cefuroxime sodium for injection sodium-tazobactam (5: 1), Youbang Fukang Medicine Inst., Co., Ltd., Hainan provides, specification: the 0.9g/ bottle
E: cefuroxime sodium for injection sodium-tazobactam (8: 1), Youbang Fukang Medicine Inst., Co., Ltd., Hainan provides, specification: the 1.125g/ bottle
F: cefuroxime sodium for injection sodium-tazobactam (15: 1), Youbang Fukang Medicine Inst., Co., Ltd., Hainan provides, specification: the 0.8g/ bottle
G: cefuroxime sodium for injection sodium-tazobactam (15: 2), Youbang Fukang Medicine Inst., Co., Ltd., Hainan provides, specification: the 0.85g/ bottle
H: cefuroxime sodium for injection, Youbang Fukang Medicine Inst., Co., Ltd., Hainan provides, specification: the 2025g/ bottle
I: cefoperazone for inj sodium-tazobactam sodium (4: 1), Hainan GeneralSanyang Pharmaceutical Co., Ltd provides, specification: the 2.0g/ bottle
J: piperacillin sodium injection sodium-tazobactam (8: 1), Hainan GeneralSanyang Pharmaceutical Co., Ltd provides, specification: the 1.125g/ bottle
Test method: adopt the full dose broth dilution method determination
Test strain: clinical isolating staphylococcus aureus, escherichia coli, each two strain of Klebsiella Pneumoniae.
Result of the test sees Table 1 and table 2, and every kind of each row is all represented the result of the test to a strain bacterial strain.
Table 1: testing sample is to the MIC result (μ g/ml) of test strain
Test strain A B C D E F G H I J
Staphylococcus aureus 2 1 1 1 1 2 2 8 0.25 4
1 1 0.5 1 1 1 1 2 1 1
Escherichia coli 4 4 2 2 4 4 8 128 0.5 4
2 2 1 2 2 4 4 128 2 1
Klebsiella Pneumoniae 2 0.5 0.25 0.25 0.5 1 1 4 0.25 0.25
4 2 2 2 4 4 8 256 1 4
Table 2:MIC outcome record is single
Code Test strain Medicament contg No medicine contrast
256 128 64 32 16 8 4 2 1 0.5 0.25 0.125 0.0625
A Staphylococcus aureus - - - - - - - - + + + + + +
Staphylococcus aureus - - - - - - - - - + + + + +
Escherichia coli - - - - - - - + + + + + + +
Escherichia coli - - - - - - - - + + + + + +
Klebsiella Pneumoniae - - - - - - - - + + + + + +
Klebsiella Pneumoniae - - - - - - - + + + + + + +
B Staphylococcus aureus - - - - - - - - - + + + + +
Staphylococcus aureus - - - - - - - - - + + + + +
Escherichia coli - - - - - - - + + + + + + +
Escherichia coli - - - - - - - - + + + + + +
Klebsiella Pneumoniae - - - - - - - - - - - + + +
Klebsiella Pneumoniae - - - - - - - - + + + + + +
C Staphylococcus aureus - - - - - - - - - - + + + +
Staphylococcus aureus - - - - - - - - - - + + + +
Escherichia coli - - - - - - - - + + + + + +
Escherichia coli - - - - - - - - - + + + + +
Klebsiella Pneumoniae - - - - - - - - - - - + + +
Klebsiella Pneumoniae - - - - - - - - + + + + + +
D Staphylococcus aureus - - - - - - - - - + + + + +
Staphylococcus aureus - - - - - - - - - + + + + +
Escherichia coli - - - - - - - - + + + + + +
Escherichia coli - - - - - - - - + + + + + +
Klebsiella Pneumoniae - - - - - - - - - - + + + +
Klebsiella Pneumoniae - - - - - - - - + + + + + +
E Staphylococcus aureus - - - - - - - - - + + + + +
Staphylococcus aureus - - - - - - - - - + + + + +
Escherichia coli - - - - - - - + + + + + + +
Escherichia coli - - - - - - - - + + + + + +
Klebsiella Pneumoniae - - - - - - - - - - + + + +
Klebsiella Pneumoniae - - - - - - - + + + + + + +
F Staphylococcus aureus - - - - - - - - + + + + + +
Staphylococcus aureus - - - - - - - - - + + + + +
Escherichia coli - - - - - - - + + + + + + +
Escherichia coli - - - - - - - + + + + + + +
Klebsiella Pneumoniae - - - - - - - - - + + + + +
Klebsiella Pneumoniae - - - - - - - + + + + + + +
G Staphylococcus aureus - - - - - - - - + + + + + +
Staphylococcus aureus - - - - - - - - - - + + + +
Escherichia coli - - - - - - + + + + + + + +
Escherichia coli - - - - - - - + + + + + + +
Klebsiella Pneumoniae - - - - - - - - - - + + + +
Klebsiella Pneumoniae - - - - - - + + + + + + + +
H Staphylococcus aureus - - - - - - + + + + + + + +
Staphylococcus aureus - - - - - - - - + + + + + +
Escherichia coli - - + + + + + + + + + + + +
Escherichia coli - - + + + + + + + + + + + +
Klebsiella Pneumoniae - - - - - - - + + + + + + +
Klebsiella Pneumoniae - + + + + + + + + + + + + +
I Staphylococcus aureus - - - - - - - - - - - + + +
Staphylococcus aureus - - - - - - - - - + + + + +
Escherichia coli - - - - - - - - - - + + + +
Escherichia coli - - - - - - - - + + + + + +
Klebsiella Pneumoniae - - - - - - - - - - - + + +
Klebsiella Pneumoniae - - - - - - - - - + + + + +
J Staphylococcus aureus - - - - - - - + + + + + + +
Staphylococcus aureus - - - - - - - - - + + + + +
Escherichia coli - - - - - - - + + + + + + +
Escherichia coli - - - - - - - - - + + + + +
Klebsiella Pneumoniae - - - - - - - - - - - - + +
Klebsiella Pneumoniae - - - - - - - + + + + + + +
By table 1 and table 2 as can be seen, when the weight ratio of Cefuroxime Sodium and sodium-tazobactam is 3: 1 and 5: 1, the MIC of staphylococcus aureus, escherichia coli and Klebsiella Pneumoniae is lower than 2: 1, shows that its antibacterial effect is better.

Claims (1)

1, a kind of combination of Cefuroxime sodium and tazobactam for injection is made up of hot sodium of cephalo and sodium-tazobactam, and it is characterized in that: the weight ratio of described Cefuroxime Sodium and sodium-tazobactam is 3: 1 or 5: 1.
CNB200510090388XA 2005-08-16 2005-08-16 Composition of cefuroxime sodium and tazobactam sodium for injection Ceased CN1315477C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CNB200510090388XA CN1315477C (en) 2005-08-16 2005-08-16 Composition of cefuroxime sodium and tazobactam sodium for injection

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNB200510090388XA CN1315477C (en) 2005-08-16 2005-08-16 Composition of cefuroxime sodium and tazobactam sodium for injection

Publications (2)

Publication Number Publication Date
CN1732950A true CN1732950A (en) 2006-02-15
CN1315477C CN1315477C (en) 2007-05-16

Family

ID=36075706

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB200510090388XA Ceased CN1315477C (en) 2005-08-16 2005-08-16 Composition of cefuroxime sodium and tazobactam sodium for injection

Country Status (1)

Country Link
CN (1) CN1315477C (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102327270A (en) * 2011-03-07 2012-01-25 深圳致君制药有限公司 Beta-lactam compound antibiotic composition

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1206995C (en) * 2003-01-23 2005-06-22 深圳信立泰药业有限公司 Anti beta-bactamase antibiotic compound prepn.
CN1562040A (en) * 2004-03-15 2005-01-12 深圳市制药厂 Composition of cefuroxime and tazobatam

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102327270A (en) * 2011-03-07 2012-01-25 深圳致君制药有限公司 Beta-lactam compound antibiotic composition
CN102327270B (en) * 2011-03-07 2013-06-26 深圳致君制药有限公司 Beta-lactam compound antibiotic composition

Also Published As

Publication number Publication date
CN1315477C (en) 2007-05-16

Similar Documents

Publication Publication Date Title
Tümmler Emerging therapies against infections with Pseudomonas aeruginosa
JP5410748B2 (en) Pharmaceutical composition comprising an antibacterial agent and an active ingredient selected from carveol, thymol, eugenol, borneol and carvacrol
Spížek et al. Lincomycin, clindamycin and their applications
Porras-Gómez et al. Overview of multidrug-resistant Pseudomonas aeruginosa and novel therapeutic approaches
EP3609478B1 (en) Nanosystems comprising silver and antibiotics and their use for the treatment of bacterial infections
Cho et al. Association between biofilm formation and antimicrobial resistance in carbapenem-resistant Pseudomonas aeruginosa
Goa et al. Panipenem/betamipron
Liwa et al. Antimicrobial resistance: Mechanisms of action of antimicrobial agents
Greer Doripenem (Doribax): the newest addition to the carbapenems
Lynch III et al. Infections due to Acinetobacter baumannii–calcoaceticus complex: escalation of antimicrobial resistance and evolving treatment options
da Costa de Souza et al. Beta‐lactam resistance and the effectiveness of antimicrobial peptides against KPC‐producing bacteria
Saikia et al. Antibiotics: From Mechanism of Action to Resistance and Beyond
CN1729987A (en) Cefuroxime sodium and sulbactam sodium composition for injection
CN1732950A (en) Composition of cefuroxime sodium and tazobactam sodium for injection
CN1732949A (en) Composition of cefuroxime sodium and tazobactam sodium for injection
CN1742735A (en) Cefuroxime oral antibacnterial composition
Panda et al. Pseudomonas aeruginosa: pathogenic adapter bacteria
CN102125562B (en) Medicinal composition for injection for treating superbug
WO2010064261A1 (en) Synergistic combinations of aztreonam with the carbapenems meropenem and ertapenem
Collignon et al. Clinical importance of antimicrobial drugs in human health
Gupta et al. MULTIDRUG RESISTANCE: OVERVIEW
Al-Dahmoshi et al. Virulence and Antibiotic Resistance of Acinetobacter baumannii among Urinary Tract Infections
Tümmler aeruginosa [version 1; peer review: 2 approved]
Xiao Antimicrobial Resistance Mechanisms of Gram-Positive and Gram-Negative Bacteria
Chaudhary et al. Alternative approach to increase antibiotic sensitivity of coagulase+ ve and-ve Staphylococcus spp in planktonic and sessile cells

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
EE01 Entry into force of recordation of patent licensing contract

Assignee: Hainan whole star Pharmaceutical Co., Ltd.

Assignor: Xia Zhongning

Contract fulfillment period: 2008.8.12 to 2025.8.16 contract change

Contract record no.: 2008460000010

Denomination of invention: Composition of cefuroxime sodium and tazobactam sodium for injection

Granted publication date: 20070516

License type: Exclusive license

Record date: 2008.11.4

LIC Patent licence contract for exploitation submitted for record

Free format text: EXCLUSIVE LICENSE; TIME LIMIT OF IMPLEMENTING CONTACT: 2008.8.12 TO 2025.8.16; CHANGE OF CONTRACT

Name of requester: HAINAN QUANXING PHARMACEUTICAL CO., LTD.

Effective date: 20081104

C35 Partial or whole invalidation of patent or utility model
IW01 Full invalidation of patent right

Decision date of declaring invalidation: 20100628

Decision number of declaring invalidation: 15037

Granted publication date: 20070516